Lantheus Holdings, Inc. to Post Q1 2024 Earnings of $1.47 Per Share, Leerink Partnrs Forecasts (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) – Leerink Partnrs cut their Q1 2024 earnings per share (EPS) estimates for Lantheus in a report issued on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now expects that the medical equipment provider will post earnings per share of $1.47 for the quarter, down from their prior estimate of $1.48. The consensus estimate for Lantheus’ current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Lantheus’ Q2 2024 earnings at $1.49 EPS, FY2024 earnings at $5.92 EPS and FY2025 earnings at $5.49 EPS.

Lantheus (NASDAQ:LNTHGet Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million.

Other equities research analysts have also recently issued research reports about the company. B. Riley raised their target price on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. JMP Securities reissued a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. Finally, Truist Financial reissued a “buy” rating and set a $82.00 target price (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $104.71.

View Our Latest Stock Report on LNTH

Lantheus Price Performance

LNTH stock opened at $63.81 on Friday. The business has a fifty day moving average of $60.81 and a two-hundred day moving average of $62.88. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. The stock has a market cap of $4.37 billion, a price-to-earnings ratio of 13.75 and a beta of 0.53. Lantheus has a 52-week low of $50.20 and a 52-week high of $100.85.

Insider Activity

In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 94,545 shares of company stock valued at $6,169,936. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its holdings in Lantheus by 198.2% during the 3rd quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after buying an additional 1,426,465 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Lantheus by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider’s stock worth $317,595,000 after buying an additional 1,422,269 shares during the last quarter. Norges Bank purchased a new stake in Lantheus during the 4th quarter worth about $45,379,000. Point72 Asset Management L.P. purchased a new stake in Lantheus during the 4th quarter worth about $28,042,000. Finally, Alliancebernstein L.P. lifted its holdings in Lantheus by 18.1% during the 4th quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock worth $162,731,000 after buying an additional 489,203 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

About Lantheus

(Get Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Featured Articles

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.